After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
The investigators showed that template-free Cas9 editing is capable of repair to a predicted genotype, allowing for correction of disease-associated mutations.
Scripps Research Translational Institute has teamed with Nvidia to create a center of excellence for AI in genomics and wearable sensors.
At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
The company aims to commercialize ProstaGene's PCaTest, which uses a 16-gene panel to determine the overall outcome of a patient's prostate cancer.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
Some partners are implementing their solutions on the Azure cloud while others will accept output from Microsoft's genomics pipeline as input into their solutions.
With an SBIR Phase II grant in hand, Michigan startup Parabricks is adding both speed and AI to variant calling as it eyes a Series A round next year.
The chatbot developed with Clear Genetics follows up with patients after genetic testing and educates family members at risk for inheriting the same mutations.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.